What is Zacks Research’s Estimate for ALNY FY2024 Earnings?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Equities researchers at Zacks Research boosted their FY2024 earnings per share (EPS) estimates for shares of Alnylam Pharmaceuticals in a note issued to investors on Wednesday, November 20th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn ($2.52) per share for the year, up from their prior estimate of ($2.65). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.21) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals’ Q4 2024 earnings at ($1.00) EPS, Q1 2025 earnings at ($0.95) EPS, Q2 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($3.26) EPS, Q1 2026 earnings at $0.33 EPS, Q2 2026 earnings at $0.09 EPS, Q3 2026 earnings at $0.64 EPS and FY2026 earnings at $1.71 EPS.

A number of other equities analysts have also issued reports on ALNY. JPMorgan Chase & Co. increased their price objective on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. The Goldman Sachs Group raised Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the company from $198.00 to $370.00 in a research note on Friday, August 16th. Chardan Capital reaffirmed a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Barclays increased their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Finally, Wells Fargo & Company increased their price target on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $253.35 on Monday. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The firm has a market capitalization of $32.68 billion, a price-to-earnings ratio of -96.70 and a beta of 0.39. The business has a 50 day simple moving average of $272.74 and a 200 day simple moving average of $239.37. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. During the same period last year, the business earned $1.15 earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was down 33.3% on a year-over-year basis.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Ashton Thomas Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter worth $26,000. Huntington National Bank grew its position in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $29,000. Washington Trust Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $42,000. Finally, True Wealth Design LLC grew its position in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.